Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
International, Multicenter, Open-label, Treatment-extension Study for Subjects Who Completed a Phase 1 or Phase 2 Parental Study to Continue Receiving Treatment With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Sponsor: Sanofi
A PHASE1/PHASE2 clinical study on Neoplasm Malignant, this trial is completed. The trial is conducted by Sanofi and has accumulated 12 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — May 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 7 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Oct 2018 — Jul 2019 [monthly]
Completed PHASE1_PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .